Aurinia Pharmaceuticals Inc. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc., a foreign private issuer, on February 16, 2017. The filing serves to report a material change and incorporates a Material Change Report (Exhibit 99.1) dated February 16, 2017. The document is incorporated by reference into the Registrant's Registration Statement on Form F-10 (File No. 333-206994).
Key Financial Metrics
The provided filing text does not contain specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The filing explicitly references a "Material Change Report" dated February 16, 2017, as Exhibit 99.1. However, the text of this Form 6-K does not describe the specific nature or details of the material change.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, specific risks, contingencies, or details regarding unusual items. The document functions primarily as a cover sheet to incorporate the referenced exhibit.
Investor Verification Checklist
- Review Exhibit 99.1 (Material Change Report) to understand the specific event triggering this filing.
- Verify the details of the Registration Statement on Form F-10 (File No. 333-206994) into which this report is incorporated.
- Consult the company's most recent Form 40-F or annual report for the latest audited financial metrics, as none are present in this filing.